Results 91 to 100 of about 41,400 (225)

Liver Abscess Following Transarterial Chemoembolization [PDF]

Seminars in Interventional Radiology, 2011
Transarterial chemoembolization (TACE) alone or in combination with thermoablation is commonly used in treating primary and secondary liver malignancies.1,2 It has proven to be safe and effective in treating hepatocellular carcinoma (HCC), neuroendocrine tumors, ocular melanoma, cholangiocarcinoma, and sarcoma.
openaire   +2 more sources

Clinical Factors Associated with Dense and Wedge-Shaped Nephrograms Detected 24 h After Chemoembolization [PDF]

, 2009
This investigation aimed to evaluate patient characteristics and procedural factors associated with abnormal nephrograms encountered on noncontrast computed axial tomography (CAT) obtained 24-h after transarterial chemoembolization (TACE) for primary and
Wayne L. Monsky, Anokh Pahwa, Chin-Shang Li, Richard W. Katzberg   +3 more
core   +1 more source

Efficacy and Safety of Second‐Line Lenvatinib After First‐Line Durvalumab Plus Tremelimumab in Unresectable Hepatocellular Carcinoma

Hepatology Research, EarlyView.
ABSTRACT Background There is a paucity of data regarding the efficacy and safety of lenvatinib as a second‐line treatment following first‐line combination immunotherapy with durvalumab and tremelimumab (Dur + Tre). Methods This retrospective multicenter study included 14 patients with unresectable hepatocellular carcinoma who received lenvatinib after ...
Ryoichi Miura, Tomokazu Kawaoka, Saki Sueda, Aiko Tanaka, Kou Hashimoto, Tomoaki Emori, Yasutoshi Fujii, Hatsue Fujino, Atsushi Ono, Eisuke Murakami, Daiki Miki, Shinsuke Uchikawa, Nami Mori, Keiji Tsuji, Yosuke Suehiro, Keiichi Masaki, Michihiro Nonaka, Kenji Yamaoka, Yoshio Katamura, C. Nelson Hayes, Masataka Tsuge, Shiro Oka   +21 more
wiley   +1 more source

Transarterial Chemoembolization for Hepatocellular Carcinoma [PDF]

Seminars in Interventional Radiology, 2009
Hepatocellular carcinoma (HCC) is the fifth most common malignancy in the world and is responsible for ~500,000 deaths worldwide annually.1 The incidence almost equals the mortality. It is the most common cause of death in patients with compensated liver cirrhosis. HCC usually arises in the setting of chronic liver disease, commonly from hepatitis B, C,
openaire   +2 more sources

Prospective Phase II trial of drug-eluting bead chemoembolization for liver transplant candidates with hepatocellular carcinoma and marginal hepatic reserve. [PDF]

, 2019
Purpose: To determine whether chemoembolization using drug-eluting beads (DEB-TACE) is safe and effective for liver transplantation candidates with liver-limited hepatocellular carcinoma (HCC) without vascular invasion and baseline hepatic dysfunction ...
Fidelman, Nicholas, Johanson, Curt, Kelley, R Kate, Kerlan, Robert K, Kohi, Maureen P, Kohlbrenner, Ryan M, Kolli, K Pallav, Lehrman, Evan D, Roberts, John P, Taylor, Andrew G, Yao, Francis Y   +10 more
core   +1 more source

Clinical Significance of Anti‐Atezolizumab Antibodies in Patients With Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab

Hepatology Research, EarlyView.
ABSTRACT Aim Systemic therapy is required for unresectable hepatocellular carcinoma (HCC). Atezolizumab plus bevacizumab (ATZ/BEV) is the recommended first‐line treatment for HCC; however, the development of anti‐drug antibodies (ADAs) against ATZ may impair its therapeutic efficacy. Although ADAs have been reported in other cancers treated with immune
Keishi Ouchi, Jun Inoue, Masashi Ninomiya, Mio Tsuruoka, Kosuke Sato, Kotaro Doi, Kengo Watanabe, Tomoya Sasazaki, Atsushi Masamune   +8 more
wiley   +1 more source

Immune Checkpoint Inhibitor–Based Adjuvant Treatment Versus Surveillance in Curatively Treated Hepatocellular Carcinoma: a Systematic Review and Meta‐Analysis

Journal of Gastroenterology and Hepatology, EarlyView.
ABSTRACT Background Effective adjuvant treatments in resected or ablated hepatocellular carcinoma (HCC) were elusive over the preceding decades. Recently, immune checkpoint inhibitors (ICIs) have been investigated in the adjuvant setting, with conflicting results. Methods A systematic literature search was conducted in multiple databases.
Erman Akkus, Hatime Arzu Yaşar
wiley   +1 more source

Transarterial Chemoembolization [PDF]

JAMA Oncology, 2015
Howard Jack, West, Jill O, Jin
openaire   +2 more sources

Imaging appearance of treated hepatocellular carcinoma. [PDF]

, 2013
Surgical resection and imaging guided treatments play a crucial role in the management of hepatocellular carcinoma (HCC). Although the primary end point of treatment of HCC is survival, radiological response could be a surrogate end point of survival ...
AGNELLO, Francesco, BRANCATELLI, Giuseppe, CABIBBO, Giuseppe, LAGALLA, Roberto, Maida, M, MIDIRI, Massimo, Salvaggio, G   +6 more
core   +1 more source

Characterization of long‐term survivors with liver metastases from uveal melanoma diagnosed between 2005 and 2021

International Journal of Cancer, Volume 158, Issue 8, Page 2179-2185, 15 April 2026.
What's New? Liver metastasis is an indicator of life expectancy for patients with advanced uveal melanoma (UM). Data on anticipated survival time following the diagnosis of liver metastasis, however, is lacking. The present study analyzed long‐term survival among UM patients who lived three or more years after liver metastases were diagnosed.
Jona Laukhuf, Lisa Wiens, Gerd Grözinger, Helmut Dittmann, Karolin Thiel, Ulrike Leiter, Teresa Amaral, Lena Nanz, Lukas Flatz, Markus Reitmajer, Andrea Forschner   +10 more
wiley   +1 more source